stockrow
Saturday 7 November 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Revenue
- −5.30%
- EPS
- +102.0%
- Free cash flow
- −10.9%
- Total debt
- −1.51%
Quarter to June 2026, against a year earlier
0.76
0.03
+4.11%
Follow CELU
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.94 | 2.04 | 1.07 | 1.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.81) | 26.72 | (5.57) | (13.11) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.20 | 4.19 | 2.64 | 2.33 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.69) | (9.01) | (5.29) | (14.39) | |
EV/FCF |
(6.57) | (8.85) | (5.22) | (14.05) | |
Quick Ratio |
0.09 | 0.07 | 0.13 | 0.10 | |
Current Ratio |
0.11 | 0.09 | 0.15 | 0.16 | |
Net Debt/EBITDA |
(15.64) | (4.77) | (2.06) | (3.58) | |
Debt/Assets |
44.48% | 41.32% | 44.55% | 34.98% | |
Debt/Equity |
(1.20) | (1.17) | (1.26) | (1.99) | |
Asset Turnover |
0.17 | 0.17 | 0.22 | 0.33 | |
Operating CF/Net income |
(2.03) | 2.14 | 0.21 | 0.18 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(23.94) | (28.79) | (24.59) | (8.73) | |
Research and Development Expense of Revenue |
37.33% | 77.85% | 81.55% | 87.02% | |
Selling, General and Administrative Expense of Revenue |
90.94% | 238.30% | 367.06% | 176.12% | |
Intangible Assets out of Total Assets |
0.14 | 0.15 | 0.14 | 0.14 | |
Share Based Compensation of Revenue |
15.54% | 32.32% | 79.24% | 38.63% | |
Graham Net Nets |
(7.15) | (3.32) | (4.68) | (2.27) | |
Graham Number |
6.80 | 8.63 | 10.96 | 7.56 | |
Earnings Yield |
(281.67%) | (205.26%) | (323.42%) | (160.87%) | |
Free Cash Flow Yield |
(51.84%) | (23.21%) | (47.21%) | (12.32%) | |
Revenue per Share |
0.19 | 0.13 | 0.16 | 0.20 | |
Operating CF per Share |
(0.04) | 0.05 | (0.20) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | 0.05 | (0.20) | (0.16) | |
Cash per Share |
0.02 | 0.01 | 0.24 | 0.00 | |
Shareholders Equity per Share |
(1.22) | (1.21) | (1.49) | (0.76) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.22) | (1.21) | (1.49) | (0.76) | |
Free Cash Flow |
(1.11) | 1.45 | (5.10) | (4.16) | |
Working Capital |
(53.29) | (64.28) | (68.44) | (54.72) | |
Net Current Asset Value |
(125.25) | (128.44) | (133.07) | (123.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.92 | 9.87 | 9.11 | 7.74 | |
Average Payables |
19.49 | 24.21 | 24.86 | 19.99 | |
Average Inventory |
2.56 | 3.34 | 2.99 | 3.26 | |
Average Assets |
108.23 | 114.18 | 120.01 | 121.54 | |
Average Common Equity |
(30.51) | (20.38) | (14.61) | (1.41) |
Columns are period end dates · fundamentals updated 2 Nov 2026